ArticleLife science alliance2021
A serum proteome signature to predict mortality in severe COVID-19 patients.
Article in Life science alliance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 105 citations in OpenAlex.
- Temporal Proteomic Profiling of Hospitalized COVID-19 Patients Reveals Prognostic Biomarkers.Journal of proteome research · 2026Article
- Immunoglobulin sub-class levels define inter-donor plasma variability: a longitudinal dual-lab study.Molecular systems biology · 2026Article
- Structural promiscuity in the human circulatory IgA1 clonal repertoire.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Combining label-free Raman spectroscopy and machine learning to identify early biomarkers of COVID-19 disease severity and mortality.Journal of biomedical optics · 2026Article
- Plasma proteomics identifies early markers of endothelial and inflammatory activation associated with dengue disease severity in children.medRxiv : the preprint server for health sciences · 2026Article
- Proteomic Analysis of Cerebrospinal Fluid from Severe COVID-19 Patients Reveals Prognostic Biomarkers Associated with Disease Outcome.Proteomics. Clinical applications · 2026Article
- Liquid Biopsy-Multiomics Link Adhesion Pathway Dysregulation to Kidney Injury Severity.Kidney international reports · 2025Article
- Extreme MetaboHealth scores in three cohort studies associate with plasma protein markers for inflammation and cholesterol transport.Immunity & ageing : I & A · 2025Article
- Plasma proteomics identifies molecular subtypes in sepsis.Critical care (London, England) · 2025Article
- Depletion of IGFALS Serum Level up to 3 Months After Cardiac Surgery, with Exploration of Potential Relationships to Surrogates of Organ Failures and Clinical Outcomes.Current issues in molecular biology · 2025Article
- Differences in biomarker levels and proteomic survival prediction across two COVID-19 cohorts with distinct treatments.iScience · 2025Article
- Multi-omic signatures of host response associated with presence, type, and outcome of enterococcal bacteremia.mSystems · 2025Article
- Multitiered Proteome Analysis Displays the Hyperpermeability of the Rheumatoid Synovial Compartment for Plasma Proteins.Molecular & cellular proteomics : MCP · 2025Article
- Dynamic Cellular Proteome Remodeling during SARS-CoV-2 Infection. Identification of Plasma Protein Readouts.Journal of proteome research · 2025Article
- What Can Proteomics Tell us About COVID-19 Infections? Mass Spectrometry as a Tool to Find New Proteins as Biomarkers.Current protein & peptide science · 2025Review
- Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.Current medicinal chemistry · 2025Article
- Ethyl palmitate ameliorates lethal endotoxemia by inducing hepatic fetuin-A secretion: anJournal of thoracic disease · 2024Article
- STAVER: a standardized benchmark dataset-based algorithm for effective variation reduction in large-scale DIA-MS data.Briefings in bioinformatics · 2024Article
- Unbiased plasma profiling using pre-selected RNA aptamer pools predicts mortality in COVID-19 and identifies protein risk factors.Molecular therapy. Nucleic acids · 2024Article
- The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.International journal of molecular sciences · 2024Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we recorded serum proteome profiles of 33 severe COVID-19 patients admitted to respiratory and intensive care units because of respiratory failure. We received, for most patients, blood samples just after admission and at two more later time points. With the aim to predict treatment outcome, we focused on serum proteins different in abundance between the group of survivors and non-survivors. We observed that a small panel of about a dozen proteins were significantly different in abundance between these two groups. The four structurally and functionally related type-3 cystatins AHSG, FETUB, histidine-rich glycoprotein, and KNG1 were all more abundant in the survivors. The family of inter-α-trypsin inhibitors, ITIH1, ITIH2, ITIH3, and ITIH4, were all found to be differentially abundant in between survivors and non-survivors, whereby ITIH1 and ITIH2 were more abundant in the survivor group and ITIH3 and ITIH4 more abundant in the non-survivors. ITIH1/ITIH2 and ITIH3/ITIH4 also showed opposite trends in protein abundance during disease progression. We defined an optimal panel of nine proteins for mortality risk assessment. The prediction power of this mortality risk panel was evaluated against two recent COVID-19 serum proteomics studies on independent cohorts measured in other laboratories in different countries and observed to perform very well in predicting mortality also in these cohorts. This panel may not be unique for COVID-19 as some of the proteins in the panel have previously been annotated as mortality markers in aging and in other diseases caused by different pathogens, including bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.